Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, October 8, 2024
"Urece Tablets" (Dotinurad) Approved In Thailand For Gout And Hyperuricemia
Wednesday, October 2, 2024
Eisai Commences Business Activities At New Pharma Sales Subsidiary In Saudi Arabia
Tuesday, September 24, 2024
Rozebalamin(R) for Injection 25 mg (Mecobalamin) Approved in Japan for Amyotrophic Lateral Sclerosis
Anticancer Agent "Tasfygo(R) Tablets 35mg" (Tasurgratinib Succinate) Approved in Japan for Biliary Tract Cancer with FGFR2 Gene Fusions or Rearrangements
Tuesday, September 17, 2024
LENVIMA(R) (lenvatinib) Plus KEYTRUDA(R) (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)
Thursday, September 5, 2024
Eisai Accelerates Progress in Oncology Research with New Data at ESMO Congress 2024
Monday, September 2, 2024
Eisai Announces Status Relating to Acquisition of Own Shares
Thursday, August 22, 2024
Leqembi (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain
Wednesday, August 14, 2024
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in the United Arab Emirates
Tuesday, August 6, 2024
Eisai: Update Regarding the Regulatory Status of LEQEMBI Subcutaneous Formulation

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: